Email updates

Keep up to date with the latest news and content from Radiation Oncology and BioMed Central.

Open Access Research

Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy

Jennifer A Dorth1*, Leonard R Prosnitz2, Gloria Broadwater3, Anne W Beaven4 and Chris R Kelsey2

Author Affiliations

1 Department of Radiation Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA

2 Department of Radiation Oncology, Duke Cancer Institute, Durham, NC, USA

3 Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA

4 Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA

For all author emails, please log on.

Radiation Oncology 2012, 7:100  doi:10.1186/1748-717X-7-100

Published: 21 June 2012

Abstract

Objective

To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL).

Methods

Patients with stage I-IV DLBCL treated from 1995–2009 at Duke Cancer Institute who achieved a complete response to chemotherapy were reviewed. In-field control, event-free survival, and overall survival were calculated using the Kaplan-Meier method. Dose response was evaluated by grouping treated sites by delivered radiation dose.

Results

105 patients were treated with RT to 214 disease sites. Chemotherapy (median 6 cycles) was R-CHOP (65%), CHOP (26%), R-CNOP (2%), or other (7%). Post-chemotherapy imaging was PET/CT (88%), gallium with CT (1%), or CT only (11%). The median RT dose was 30 Gy (range, 12–40 Gy). The median radiation dose was higher for patients with stage I-II disease compared with patients with stage III-IV disease (30 versus 24.5 Gy, p < 0.001). Five-year in-field control, event-free survival, and overall survival for all patients was 94% (95% CI: 89-99%), 84% (95% CI: 77-92%), and 91% (95% CI: 85-97%), respectively. Six patients developed an in-field recurrence at 10 sites, without a clear dose response. In-field failure was higher at sites ≥ 10 cm (14% versus 4%, p = 0.06).

Conclusion

In-field control was excellent with a combined modality approach when a complete response was achieved after chemotherapy without a clear radiation dose response.